Expression and activity analyses of CTLA4 in peripheral blood lymphocytes in systemic lupus erythematosus patients

被引:7
作者
Hirashima, M [1 ]
Fukazawa, T [1 ]
Abe, K [1 ]
Morita, Y [1 ]
Kusaoi, M [1 ]
Hashimoto, H [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Rheumatol & Internal Med, Bunkyo Ku, Tokyo 1138421, Japan
关键词
CTLA4; lupus nephritis; systemic lupus erythematosus;
D O I
10.1191/0961203304lu488oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to determine the expression and activity of CTLA4 in T-cells of systemic lupus erythematosus (SLE) patients. Expression of CTLA4 on freshly isolated peripheral blood T-cells was evaluated in 33 SLE patients. and 25 controls using flow cytometry. The T-cells from 19 SLE patients and 22 controls were stimulated and cultured with Chinese hamster ovary cells expressing CD80 (CHO-CD80) or with CHO cells. T-cell proliferation was determined with [H-3] thyrnidine incorporation (CPM), and the inhibitory effect of CTLA4 on T-cell proliferation was evaluated by the ratio of CPM for T-cells with CHO-CD80 cells to that of T-cells with CHO cells (the CHO-CD80/CHO ratio). Intracellular CTLA4 expression in freshly isolated peripheral blood T-cells was significantly higher in SLE patients than the controls (P < 0.05), but there was no correlation with clinical features or disease activity. The CHO-CD80/CHO ratio of SLE patients was significantly higher than that of the controls (P < 0.05). Among SLE patients, the CHO-CD80/CHO ratio of patients with lupus nephritis was significantly higher than that of patients without lupus nephritis (P < 0.05). In conclusion, our data suggest that CTLA4 expression is not impaired in SLE patients, but there is a possibility of decreased inhibitory effect of CTLA4 involved in the pathogenesis of SLE.
引用
收藏
页码:24 / 31
页数:8
相关论文
共 32 条
[1]   Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population [J].
Ahmed, S ;
Ihara, K ;
Kanemitsu, S ;
Nakashima, H ;
Otsuka, T ;
Tsuzaka, K ;
Takeuchi, T ;
Hara, T .
RHEUMATOLOGY, 2001, 40 (06) :662-667
[2]  
Alegre ML, 1996, J IMMUNOL, V157, P4762
[3]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[4]  
Boulougouris G, 1998, J IMMUNOL, V161, P3919
[5]   CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression [J].
Carreno, BM ;
Bennett, F ;
Chau, TA ;
Ling, V ;
Luxenberg, D ;
Jussif, J ;
Baroja, ML ;
Madrenas, J .
JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1352-1356
[6]  
COHEN PL, 1993, J INVEST DERMATOL, V100, pS69, DOI 10.1038/jid.1993.26
[7]   The T cell enigma in lupus [J].
Dayal, AK ;
Kammer, GM .
ARTHRITIS AND RHEUMATISM, 1996, 39 (01) :23-33
[8]   CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus [J].
Donner, H ;
Rau, H ;
Walfish, PG ;
Braun, J ;
Siegmund, T ;
Finke, R ;
Herwig, J ;
Usadel, KH ;
Badenhoop, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) :143-146
[9]   TREATMENT OF MURINE LUPUS WITH CTLA4IG [J].
FINCK, BK ;
LINSLEY, PS ;
WOFSY, D .
SCIENCE, 1994, 265 (5176) :1225-1227
[10]   A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families [J].
Gaffney, PM ;
Kearns, GM ;
Shark, KB ;
Ortmann, WA ;
Selby, SA ;
Malmgren, ML ;
Rohlf, KE ;
Ockenden, TC ;
Messner, RP ;
King, RA ;
Rich, SS ;
Behrens, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14875-14879